Aisling Capital
Venture capitalNew York · Seed–Series C · 17 people tracked
Also known as AISLING CAPITAL LLC · AISLING CAPITAL MANAGEMENT LP
Investment thesis
Aisling Capital invests in companies developing and commercializing important, innovative healthcare products, services, and technologies. Since 2000, the firm has built a track record of deploying and returning capital, managing $1.8 billion in assets. Its portfolio spans biotechnology and therapeutics companies advancing novel treatments across areas such as cell therapies, rare diseases, and psychedelics-based medicine.
Source: firm website, verified Aug 3, 2026.
Team · 17 people
from the firm's website & public directories
What they invest in
from 39 of 123 portfolio companiesBiotech ×32Healthtech ×26Medical Devices ×18Advanced Manufacturing ×2AI & Machine Learning ×2Digital Health ×2FemTech ×1Hardware ×1
HQs:United States×32Denmark×1Vietnam×1
Investments · 123 tracked
founders shown can be your intro pathMonte Rosa Therapeutics is a biopharmaceutical company developing molecular glue degrader (MGD) therapeutics using its QuEEN discovery engine, targeting oncology, neuroscience, and immune-mediated diseases.
AI & Machine LearningBiotechHealthtechBoston, US
Alexander Mayweg(Director)Bradley Bolzon(Director)Markus Warmuth(M.D., Chief Executive Officer)Ali Behbahani(Director)Kim Blackwell(Director)Sharon Townson(Ph.D., Chief Scientific Officer)
HealthtechOrlando, US
Lothar Koob(Director)Alan B Connaughton(Executive Officer)Amy R Brooks(Executive Officer)Charles W Federico(Director)Carmen L Bringgold(Director)Peter J Mariani(Executive Officer)
Board seatSteven ElmsJosh Bilenker· per SEC Form D
BiotechHouston, US
Juan Vera(Executive Officer, Director)Mark Reddish(Director)Glynn Wilson(Executive Officer, Director)David Laskow-Pooley(Director)Sherry Grisewood(Director)John Bonfiglio(Executive Officer, Director)
Board seatSteven Elms· per SEC Form D · $16.1M raise · filed Dec 2024
Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.
BiotechHealthtechMedical DevicesWayne, US
Neal Walker(Executive Officer, Director)Joseph Monahan(Executive Officer)Hugh Davis(Executive Officer, Director)James Loerop(Executive Officer)Kevin Balthaser(Executive Officer)Kamil Ali-Jackson(Executive Officer)
BiotechRedwood City, US
Thomas Butler(Executive Officer, Director)Ramses Erdtmann(Director, Executive Officer)
Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases.
BiotechHealthtechMedical DevicesNorthbrook, US
Jeffrey M. Dayno, M.D.(President and Chief Executive Officer)Patrick Morris(Secretary and Treasurer)Jeffrey Aronin(Director)Aaron Royston(Director)Dr. Andreas Wicki(Director)Jack Nielsen(Director)
Johnson & Johnson is a diversified healthcare company operating across 260 subsidiary companies with approximately 138,000 employees globally.
BiotechHealthtechMedical DevicesNew Brunswick, US
Biotech
Paul F. Truex(Director)Asish K. Xavier, Ph.D.(Director)Michael Panaccio, Ph.D.(Director)Armen Shanafelt, Ph.D.(Director)Dinesh V. Patel, PhD(Executive Officer, Director)Harold E. Selick, Ph.D.(Director)
Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.
BiotechCambridge, US
Kristina Burow(Director)Katrine Bosley(Director)Amir Nashat(Director)Michael Gilman(Director)Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)
Earlens develops a hearing aid that vibrates the eardrum directly instead of using speakers to amplify sound, enabling amplification across a broad audible frequency range including higher frequencies important for speech understanding.
HardwareHealthtechMedical DevicesMenlo Park, US
William M. Facteau(Executive Officer, Director)Bernard Shay(Executive Officer)Rodney Perkins, M.D.(Director)Henry Plain, Jr.(Director)Phil Lyons(Executive Officer)Steven A. Elms(Director)
Board seatSteven Elms· per SEC Form D
BiotechCambridge, US
David Kirske(Executive Officer)Adam Craig(Executive Officer, Director)Shaan Gandhi(Director)Dhvanit I Shah(Chief Executive Officer of the Issuer)
BoardGeoff Meyerson(Director)Raymond Kelleher(Director)
Board seatEric Aguiar· per SEC Form D · filed Oct 2024
Invitae provides genetic testing services to patients and clinicians across the United States, offering broad test offerings and genetic counseling to inform health decisions at every stage of life.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Shelly Guyer(Executive Officer)Eric Aguiar(Director)Sean George(Executive Officer, Director)Christine Gorjanc(Director)Geoffrey Crouse(Director)Lee Bendekgey(Executive Officer)
Board seatEric Aguiar· per SEC Form D · $6M raise · filed Jun 2017
HealthtechNew York, US
Kristi Henderson(Director)Julian Flannery(Executive Officer, Director)Arif Nathoo(Director)Rick Buhrman(Director)Dennis Purcell(Executive Officer)Aftab Kherani(Director)
Board seatAyman Sabi· per SEC Form D · $16M raise · filed Apr 2021
Asensus Surgical (formerly TransEnterix) develops surgical robotics, advanced visualization, and instrumentation technology for surgeons.
HealthtechMedical DevicesRoboticsMorrisville, US
Anthony Fernando(Executive Officer)Paul A LaViolette(Director)Jane H Hsiao(Director)William N Kelley(Director)Andrea Biffi(Director)William, Jr. N Starling(Director)
Board seatAftab Kherani· per SEC Form D
Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Joshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)
BoardKristina Burow(Director)Ali Satvat(Director)David Schenkein(Director)
Board seatSteven ElmsAftab Kherani· per SEC Form D
Agile Therapeutics develops and markets contraceptive and women's health products using its proprietary Skinfusion® transdermal technology platform.
BiotechFemTechHealthtech
Katie MacFarlane(Executive Officer)Karen Hong(Director)William T. McKee(Director)John Hubbard(Director)Scott M. Coiante(Executive Officer)Al Altomari(Executive Officer, Director)
BiotechMendham, US
Abel De La Rosa(Director)Iyona Rajkomar(Director)Douglas Mayers(Executive Officer)Benjamin Rovinski(Director)Patrick Higgins(Director)Tamra Adams(Executive Officer)
Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.
BiotechHealthtechMedical DevicesDenmark, DK
Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)
BiotechRedwood City, US
William Robinson(Director)Lawrence Steinman(Director)Tito Serafini(Executive Officer, Director)Franklin Berger(Director)Brian Atwood(Director)
Biohaven is a biopharmaceutical company focused on discovering and developing treatments in immunology, obesity, neuroscience, and oncology, including approved migraine medications.
BiotechHealthtechMedical Devices
CalciMedica is a clinical-stage biopharmaceutical company developing therapies that inhibit CRAC calcium channels to address acute and chronic inflammatory, immunologic, and cardiopulmonary diseases.
BiotechHealthtechMedical Devices
Catalent is a global contract development and manufacturing organization (CDMO) that develops, manufactures and supplies pharmaceuticals, biologics, gene and cell therapies, and consumer health products.
Advanced ManufacturingBiotechHealthtechSomerset, US
John R. Chiminski(Executive Officer, Director)Jack L. Stahl(Director)Madhavan Balachandran(Director)J. Martin Carroll(Director)Rolf A. Classon(Director)Rosemary Crane(Director)
Chimerix is a biopharmaceutical company developing therapies for rare diseases and cancers, with a focus on advancing treatments through biomarker-driven approaches and precision medicine.
BiotechHealthtechMedical Devices
Pharmaceutical company developing medicines and vaccines for patient health and treatment.
BiotechHealthtechSan Diego, US
Jeffrey Stein(Executive Officer, Director)Steve Elms(Director)Dan Burgess(Director)Scott Rocklage(Director)Ted Schroeder(Director)Kevin Forrest(Executive Officer)
HealthtechCarlsbad, US
Stephen Loomis(Executive Officer)M Bolyard(Director)Brian Dovey(Director)Josh Baltzell(Director)Mary Fisher(Executive Officer, Director)Daniell Turner III(Director)
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Lou Lange(Founder)
HealthtechMenlo Park, US
LUIS PENA(Executive Officer)CHRISTOPHER GRIFFITH(Executive Officer)KATHLEEN SEBELIUS(Director)DAVID E. COHEN(Director)FRED CRAVES(Director)THOMAS G. WIGGANS(Executive Officer, Director)
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Executive Officer, Director)Ivan Trifunovich(Director)John Wesley(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Fund performance · per public LP disclosures · 5
as of Sep 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Aisling Capital IV, L.P.LPs: Pennsylvania Public School Employees' Retirement System, Andrew W. Mellon Foundation | 2015 | — | 11.6% | 1.74x | 0.68x |
| Aisling Capital IIILPs: New York City Police Pension Fund | 2008 | — | 26.4% | 2.38x | 2.38x |
| Aisling Capital III, L.P.LPs: California Public Employees' Retirement System, Pennsylvania Public School Employees' Retirement System, Empire State Development – New York Ventures +6 more | 2008 | — | 26.5% | 2.38x | 2.38x |
| Aisling Capital IILPs: New York City Police Pension Fund | 2006 | — | 0.6% | 1.04x | 1.04x |
| Aisling Capital II, L.P.LPs: California Public Employees' Retirement System, Pennsylvania Public School Employees' Retirement System, Empire State Development – New York Ventures +5 more | 2005 | — | 0.9% | 1.06x | 0.99x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- What stage does Aisling Capital invest at?
- Aisling Capital invests at the Seed, Series A, Series B, Series C stages.
- What sectors does Aisling Capital focus on?
- Aisling Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Aisling Capital located?
- Aisling Capital is headquartered in New York, US.
Co-investors · 28
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
RA Capital invests in public and private healthcare and life science companies developing pharmaceuticals, medical devices, and diagnostic tools. The firm operates as a crossover fund across multiple investment stages.
Foresite Capital is a multi-stage investment firm focused on healthcare and life sciences, backing companies across all stages of growth. It applies a data science-driven approach to invest in businesses leveraging biology and big data to transform healthcare.
The Column Group (TCG) is a venture capital firm focused on building and backing biotechnology companies, applying an edge-to-edge investment model centered on company formation with capacity for long-term private and public capital support.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
SR One is a biotechnology-focused venture capital firm that partners with founders to develop innovative science into new medicines.
Alta Partners is a venture capital firm focused on the healthcare and life sciences sector, backing entrepreneurs building companies across biotechnology, therapeutics, and healthcare innovation.
Longwood Fund is a Boston-based venture firm focused on discovering and building science-based companies, with a team spanning doctors, scientists, entrepreneurs, and investors.
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
▶16 more co-investors
Drive CapitalVersant VenturesSV Health InvestorsHBM PartnersUS Venture PartnersGeneral AtlanticFlare Capital PartnersJohnson & Johnson Innovation – JJDCDomain AssociatesFlagship PioneeringMorgenthalerFrazier Healthcare PartnersHealthQuest CapitalACORN BIOVENTURESJumpstart FoundryDe Novo Ventures
Firms observed investing alongside Aisling Capital, from public investor directories. Shared companies are the overlap with Aisling Capital's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.